Shanxi Hongxiang Yixintang Pharmaceutical Co., Ltd. announced that it will receive CNY 120,000,000 in an equity round of funding on October 25, 2016. The transaction will include participation from existing investor, Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. (SZSE:002727). On closing, the registered capital of the company will increase from CNY 18,000,000 to CNY 138,000,000. On closing, the investor will continue to retain its 100% stake in the company. As part of the transaction, the investor will acquire 86.956522% stake in the increased capital of the company. The transaction was approved at the 28th session of the 3rd directorate of the investor. The transaction is further subject to approval from the shareholders of the investor. The company reported total assets of CNY 271,091,241.68, liabilities of CNY 270,946,850.48, net assets of CNY 144,391.20, operating revenues of CNY 108,619,975.63, and net profit of CNY -1,165,744.91 for the year ended December 31, 2015.